168 related articles for article (PubMed ID: 34354590)
1. Patient Preferences for Attributes of Chemotherapy for Lung Cancer: Discrete Choice Experiment Study in Japan.
Sugitani Y; Ito K; Ono S
Front Pharmacol; 2021; 12():697711. PubMed ID: 34354590
[TBL] [Abstract][Full Text] [Related]
2. A Study of Patient Preferences for the Treatment of Non-small Cell Lung Cancer in Western China: A Discrete-Choice Experiment.
Liu F; Hu H; Wang J; Chen Y; Hui S; Hu M
Front Public Health; 2021; 9():653450. PubMed ID: 33842426
[No Abstract] [Full Text] [Related]
3. Patients' preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan.
Omori Y; Enatsu S; Cai Z; Ishiguro H
Breast Cancer; 2019 Sep; 26(5):652-662. PubMed ID: 30949915
[TBL] [Abstract][Full Text] [Related]
4. Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China.
Sun H; Wang H; Xu N; Li J; Shi J; Zhou N; Ni M; Hu X; Chen Y
Patient Prefer Adherence; 2019; 13():1701-1709. PubMed ID: 31631985
[TBL] [Abstract][Full Text] [Related]
5. Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: Results From a Large Survey Across Seven European Countries Using a Discrete Choice Experiment.
Fiorino G; Bent-Ennakhil N; Varriale P; Braegger F; Hoefkens E
Inflamm Bowel Dis; 2024 Mar; ():. PubMed ID: 38503480
[TBL] [Abstract][Full Text] [Related]
6. Comparing the Relative Importance of Attributes of Metastatic Renal Cell Carcinoma Treatments to Patients and Physicians in the United States: A Discrete-Choice Experiment.
González JM; Doan J; Gebben DJ; Boeri M; Fishman M
Pharmacoeconomics; 2018 Aug; 36(8):973-986. PubMed ID: 29869777
[TBL] [Abstract][Full Text] [Related]
7. Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment.
Uemura H; Matsubara N; Kimura G; Yamaguchi A; Ledesma DA; DiBonaventura M; Mohamed AF; Basurto E; McKinnon I; Wang E; Concialdi K; Narimatsu A; Aitoku Y
BMC Urol; 2016 Nov; 16(1):63. PubMed ID: 27814714
[TBL] [Abstract][Full Text] [Related]
8. Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study.
Mansfield C; Botha W; Vondeling GT; Klein K; Wang K; Singh J; Hackshaw MD
Breast Cancer; 2023 Jan; 30(1):23-35. PubMed ID: 36074320
[TBL] [Abstract][Full Text] [Related]
9. Balancing benefits and risks in lung cancer therapies: patient preferences for lung cancer treatment alternatives.
Oliveri S; Lanzoni L; Veldwijk J; de Wit GA; Petrocchi S; Janssens R; Schoefs E; Smith MY; Smith I; Nackaerts K; Vandevelde M; Louis E; Decaluwé H; De Leyn P; Declerck H; Petrella F; Casiraghi M; Galli G; Garassino MC; Girvalaki C; Huys I; Pravettoni G
Front Psychol; 2023; 14():1062830. PubMed ID: 37425173
[TBL] [Abstract][Full Text] [Related]
10. Stated Preferences in Non-Small-Cell Lung Cancer: A Discrete Choice Experiment.
Meirelles I; Magliano C
Patient Prefer Adherence; 2021; 15():911-917. PubMed ID: 33958859
[TBL] [Abstract][Full Text] [Related]
11. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes.
Hauber AB; Nguyen H; Posner J; Kalsekar I; Ruggles J
Curr Med Res Opin; 2016; 32(2):251-62. PubMed ID: 26549576
[TBL] [Abstract][Full Text] [Related]
12. Patient Preferences Regarding Rheumatoid Arthritis Therapies: A Conjoint Analysis.
Louder AM; Singh A; Saverno K; Cappelleri JC; Aten AJ; Koenig AS; Pasquale MK
Am Health Drug Benefits; 2016 Apr; 9(2):84-93. PubMed ID: 27182427
[TBL] [Abstract][Full Text] [Related]
13. Hematologists' Preferences for First-line Therapy Characteristics for Multiple Myeloma in Japan: Attribute Rating and Discrete Choice Experiment.
Bolt T; Mahlich J; Nakamura Y; Nakayama M
Clin Ther; 2018 Feb; 40(2):296-308.e2. PubMed ID: 29358004
[TBL] [Abstract][Full Text] [Related]
14. Patient Preferences for Preventive Migraine Treatments: A Discrete-Choice Experiment.
Mansfield C; Gebben DJ; Sutphin J; Tepper SJ; Schwedt TJ; Sapra S; Shah N
Headache; 2019 May; 59(5):715-726. PubMed ID: 30861110
[TBL] [Abstract][Full Text] [Related]
15. Patient preferences and predicted relative uptake for targeted therapies in metastatic colorectal cancer: a discrete choice experiment.
Wong XY; Lim AQJ; Shen Q; Chia JWK; Chew MH; Tan WS; Wee HL
Curr Med Res Opin; 2020 Oct; 36(10):1677-1686. PubMed ID: 32609014
[TBL] [Abstract][Full Text] [Related]
16. Patient preferences for objective quality metrics during community pharmacy selection: A discrete choice experiment.
Patterson JA; Holdford DA; Harpe SE
Res Social Adm Pharm; 2019 Jun; 15(6):641-649. PubMed ID: 30143466
[TBL] [Abstract][Full Text] [Related]
17. Assessment of patients' preferences for new anticancer drugs in China: a best-worst discrete choice experiment on three common cancer types.
Feng Z; Meng J; Sun Y; Xie T; Lu W; Wang G; Geng J
BMJ Open; 2023 Jun; 13(6):e072469. PubMed ID: 37270199
[TBL] [Abstract][Full Text] [Related]
18. The importance of drug adverse effects compared with seizure control for people with epilepsy: a discrete choice experiment.
Lloyd A; McIntosh E; Price M
Pharmacoeconomics; 2005; 23(11):1167-81. PubMed ID: 16277551
[TBL] [Abstract][Full Text] [Related]
19. A Bayesian hierarchical model for discrete choice data in health care.
Antonio ALM; Weiss RE; Saigal CS; Dahan E; Crespi CM
Stat Methods Med Res; 2018 Dec; 27(12):3544-3559. PubMed ID: 28417689
[TBL] [Abstract][Full Text] [Related]
20. Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment.
Garcia-Dominguez JM; Muñoz D; Comellas M; Gonzalbo I; Lizán L; Polanco Sánchez C
Patient Prefer Adherence; 2016; 10():1945-1956. PubMed ID: 27713622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
